BP897 is a partially selective D3 dopamine receptor agonist.

BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

BPN14770 (BPN-14770) is an allosteric inhibitor of phosphodiesterase 4D (PDE4D) with IC50 of 7.8 and 7.4 nM for human PDE4D7 and PDE4D3 respectively, displays 16-fold less potent against monomeric form of PDE4D lacking the UCR1 dimerization domain (PDE4D2

BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM.

BPO-27 racemate is a potent CFTR inhibitor with an IC50 of 8 nM.

BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM.

BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM.

BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.

BPTES is a selective inhibitor of Glutaminase GLS1 (KGA)

BPTU is an Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM).

BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.

BQ-788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells); poorly inhibited the binding to ET A receptors in human neuroblastoma cell line SK-N-MC cells (IC(50), 1300 nM).

BQCA is a potent muscarinic M1 receptor positive allosteric modulator with selectivity for M1 over M2-M5.

BQU-082 is a novel potent small GTPase Ral (Ras-like) inhibitor with IC50 of 1.7 uM, displays a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay..

BQU57 is a potent and selective GTPase Ral Inhibitor.

BR101549 (BR-101549) is a novel PPARγ non-TZD agonist with EC50 of 1.73 uM (Amax 120%)..

BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8  nM.

BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40  nM (inhibition of hC3a induced Ca2+ release on human macrophages).

BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BRACO-19 is a potent small molecule Telomerase inhibitor (IC50=115 nM) that inhibits expression of human telomerase reverse transcriptase (hTERT).

BRACO19 is a telomerase inhibitor that stabilizes G-quadruplexes, targeting telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.

Bractoppin is a potent, small-molecule chemical inhibitor that specific selectively blocks phosphopeptide recognition by the BRCA1 tBRCT domain with binding IC50 of 74 nM; shows no inhibition for recognition of cognate biotinylated phosphopeptides to the TOPBP1 tBRCT 7/8, or GRB2 SH2 proteins; engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket; inhibits substrate recognition detected by Förster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51; selectively interrupts BRCA1 tBRCT-dependent signals evoked by DNA damage.

Bradanicline (TC-5619) is an experimental pharmaceutical drugthat acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors.

Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.

B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).

B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 uM and 2 nM for A375 proliferation and A375 p-ERK respectively.

BRAF inhibitor is a potent BRAF inhibitor.

Bragsin1 (Bragsin 1) is a specific inhibitor of the ArfGEF BRAG2, affects the trans-Golgi network in a BRAG2- and Arf-dependent manner in cells (IC50=3 uM).

Bragsin2 is a novel PH-domain-binding inhibitor,inhibiting BRAG2-mediated Arf GTPase activation.

branopadol(GRT-6005) is a novel first in class compounds with potent agonist activity on ORL-1 (opioid receptor like -1) and the well established mu opioid receptor.

Brassinin is a Inducer of phase II enzymes. Moderate and competitive indoleamine 2,3-dioxygenase inhibitor (Ki = 98 μM). Shows chemopreventive effects in vivo. Orally active.

Brassinolide is a predominant plant growth modulator that regulate plant cell elongation. It is active against herpes and arena viruses.

BRD 0476 (ML187) is a selective, moderate inhibitor of ubiquitin-specific peptidase 9X (USP9X), inhibits pancreatic β-cell apoptosis that inhibits IFN-γ-induced JAK2 and STAT1 signaling to promote β-cell survival.

BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively.

BRD 7389 is an inhibitor of ribosomal S6 kinases (RSK) with IC50 of 1.5 uM, 2.4 uM, and 1.2 uM for RSK1, RSK2, and RSK3, respectively.

BRD 8184 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, weakly inhibits HDAC2 and HDAC8 (IC50=0.34 and 1.33 uM),has no activity for HDAC4 (IC50>30 uM)..

BRD 8430 is a potent, selective class I HDAC inhibitor (HDAC1>2 >3) with IC50 of 69 nM/560/1300 nM for HDAC1/2/3, respectively.

BRD 8899 is a potent and selective inhibitor of the serine/threonine kinase STK33 with IC50 of 0.11 nM (25 uM ATP).

BRD 9876 is an ATP- and ADP-competitive Eg5 (kinesin-5) inhibitor with Ki of 4 nM, selectively inhibits microtubule-bound Eg5 and inhibits multiple myeloma cell growth (IC50=2.2 uM).

BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.

BRD0705 is a potent, paralog-selective GSK3α inhibitor with IC50 of 66 nM, 8-fold selectivity over GSK3β (IC50=515 nM).

BRD10330 (BRD-10330) is a small molecule that upregulates IL-10 production in BMDCs.

BRD1172 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 3 nM/10 nM for GSK3α/GSK3β, respectively..

BRD1240 is a small-molecule probe that can suppress V-ATPase function, inhibits lysosomal acidification and blocks the maturation of autophagosomes to autolysosomes.

BRD1652 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 0.4 nM/4 nM for GSK3α/GSK3β respectively.

BRD1991 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity..

BRD2492 is a highly potent, selective HDAC1/2 inhibitor (IC50=2/19 nM, respectively) that displays excellent selectivity versus HDAC3 (IC50=2.08 uM, ≥110-fold selectivity) and all other HDAC isoforms, increases caspase-3 activation..

BRD2879 (BRD-2879) is a potent, selective inhibitor of IDH1-R132H mutant with IC50 of 50 nM, inhibits cell-based production of R-2HG with EC50 of 0.3 uM.

BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM, displays >20-fold selectivity over HDAC1 and HDAC2, >500-fold selectivity over other HDAC isoforms.

BRD3731 is a potent, selective GSK3β inhibitor with IC50 of 15 nM, 14-fold selectivity for GSK3β over GSK3α (IC50=215 nM).

BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.

BRD4 inhibitor Compound V is a domain-selective inhibitor of BRD4 with IC50 of 1.8 uM for BRD4 BD1, displays 6- and 16-fold selectivity for BRD4 over BRD2 and BRD3, respectively.

BRD4770 is a selective inhibitor of the histone methyltransferase G9a.

BRD50837 is a potent, selective, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 90 nM, partially lowers Gli1 expression at concentrations of 2 uM, a useful probe of Shh signaling pathway. .

BRD5459 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5529 is a small-molecule inhibitor that disrupts the interaction of CARD9-E3 ubiquitin ligase TRIM62 with IC50 of 8.6 uM.

BRD56491 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD5814 is a potent, selective, highly brain penetrant β-arrestin biased dopamine D2 receptor (D2R) antagonist with Ki of 0.27 uM.

BRD6851 is a potent, cell-active Hedgehog (Hh) pathway inhibitor with IC50 of 0.4 uM against C3H10T1/2 cells undergoing Hh-induced activation acts predominantly as Smo antagonist.

BRD7116 competitively binds to bacterial DNA gyrase, exhibits an EC50 of 200 nM for LSCe cells, with cell-non-autonomous anti-leukemia activity.

BRD-73954 is a biochemical inhibitor histone deacetylase cancer histone modification epigenetics gene regulation small molecule HDAC6 HDAC8.

BRD7552 is an inducer of transcription factor PDX1, which increases insulin expression.

BRD9092 is a nontoxic enhancer of reactive oxygen species (ROS) that strongly elevates markers of oxidative stress without causing cell death, ROS inducer..

BRD9526 is a potent, small-molecule inhibitor of the Sonic Hedgehog (Shh) pathway with EC50 of 60 nM, partially lowers Gli1 expression at concentrations of 10 uM, a useful probe of Shh signaling pathway. .

BRD9757 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM, displays >20-fold selectivity over HDAC1/3 and other HDAC isoforms..

BRD9-IN-28 is a highly potent and selective BRD7/9 bromodomain inhibitor with pIC50 of 6.9, Kd of 68 nM for BRD9.

BRD-IN-17 is a cell permeable, family VIII bromodomain tool compound with additional PB1(2) activity over and above that of PFI-3.

BRD-IN-26 is a potent bromodomain inhibitor that binds the fifth bromodomain of PB1 with a KD of 124 nM, SMARCA2B and SMARCA4 with KD values of 262 and 417 nM, respectively.

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells.

Brequinar sodium (DuP-785, Brequinar, NSC 368390) is a potent and selective inhibitor of DHODH with IC50 of 20 nM, triggers differentiation in the ER-HoxA9, U937, and THP1 cells with an ED50 of 1 uM.

Brevianamide F , also known as cyclo-(L-Trp-L-Pro), belongs to a class of naturally occurring 2,5-diketopiperazines.

Brexpiprazole is a novel D2 dopamine partial agonist.

Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.

Brigatinib (AP-26113, AP26113) is a potent, selective, second generation ALK inhibitor with IC50 of 0.62 nM, exhibits about fivefold greater potency in vitro compared with crizotinib.

Brinzolamide is a potent carbonic anhydrase II inhibitor with IC50 of 3.19 nM.

Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.

Brivaracetam(UCB-34714) is a 4-substituted pyrrolidone butanamide as agent with significant antiepileptic activity; high affinity SV2A ligand and also shows an ability to inhibit Na+ channels.

Brivudine is a thymidine analogue with antiviral activity, indicated for the early treatment of acute herpes zoster.

BRK inhibitor P21d is a potent, selective, cell permeable inhibitor of breast tumor kinase (Brk, PTK6) with IC50 of 30 nM, shows no inhibitory activity against Aurora B and Lck (IC50>20 uM).

BRL 37344 is a potent and selective β3 adrenoceptor agonist with Ki of 287 nM.

BRL 52537 is a selective κ/μ opioid receptor agonist.

BRL 54443 is a 5-HT1E and 5-HT1F receptor agonist with pKi of 8.7 and 9.25, respectively, with a weak binding affinity for 5-HT1A, 5-HT1B, 5-HT1D receptors.

BRL-15572 2Hcl is a 5-HT1D receptor antagonist with pKi of 7.9, also shows a considerable affinity at 5-HT1A and 5-HT2B receptors, exhibiting 60-fold selectivity over 5-HT1B receptor.

BRL-50481 is a novel and selective inhibitor of phosphodiesterase (PDE) 7 with a Ki value, derived from secondary (Dixon) plots, of 180±10 nM, being at least 200-fold selective for hrPDE7A1 over all other PDEs.

Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm.

Bromocriptine (2-Bromoergocriptine.

Bromocriptine (CB-154) is a dopamine D2 receptor agonist (Ki=3 nM) and and various serotonin receptors, also inhibits the release of glutamate by reversing the glutamate GLT1 transporter.

Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and used in the detection of proliferating cells.

Bromosporine is a broad spectrum bromodomain inhibitor. Accelerates FRAP recovery of BRD4 and CREBBP in cells at a concentration of 1 μM.

Bromotriazine (BTZ) is a covalent probe against bromodomain containing proteins with selectively targeting non-catalytic, highly conserved amino acid residues..

Brompheniramine maleate is a histamine H1 receptors antagonist.

BRPF1B TRIM24-IN-34 is a selective BRPF1B/TRIM24 dual inhibitor that binds with KD of 137 and 222 nM, respectively.

Brusatol (NSC 172924, (+)-Brusatol) is a quassinoid extracted from Brucea Esters, can inhibit HIF-1 signaling pathway, also is a potent Nrf2 inhibitor.

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).

BS148 (BS-148) is a potent, selective σ2 receptor agonist with pKi of 7.71, displays 25-fold selectivity over σ1.

BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. ; >40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

BS-181 is a highly selective CDK7 inhibitor with IC50 of 21 nM. ; >40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

BS-194 is a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 with IC50 values of 3, 30, 30, 250, and 90 nM respectively.

BSI-201 (Iniparib; NSC-746045) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).

BSJ-03-123 is a potent, CDK6-selective small-molecule degrader (PROTAC) that uniquely enables rapid pharmacological interrogation of CDK6-dependent functions.

BT-11 is an orally active and selective LANCL2 modulator.

BTB-1 is a small molecule inhibitor of the mitotic motor protein Kif18A.

BTK inhibitor 1 (Compound 27)

Btk inhibitor 2 is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.

BTK PROTAC 10 is a novel potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells.

BTK PROTAC 9 is a novel potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK.

BTK-030 is a novel BTK inhibitor.

BTK-IN-23 is a highly potent and selective Btk inhibitor with IC50 of 3 nM.

BTRX-335140 (CYM-53093, BTRX335140, CYM53093) is a potent, selective, orally active κ opioid receptor (KOR) antagonist with IC50 of 0.8 nM.

BTT-266 (BTT266) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction, directly binds to CaVβ3 with Kd of 3.6 uM.

BTT-369 (BTT369) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction with Ki of 2.0 uM in FP assays.

BTX161 is a thalidomide analog that mediates degradation of CKIα better than lenalidomide in human AML cells and activates DDR and p53, while stabilizing the p53 antagonist MDM2.

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.

BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.

BTZO-1 is a cardioprotective agent and Macrophage migration inhibitory factor (MIF) activator, binds to MIF with Kd of 68.6 nM, regulates ARE-mediated gene expression.

BTZO-15 is an active BTZO-1 derivative for ARE-activation with a favorable ADME-Tox profile, induces expression of heme oxygenase-1 (HO-1) and inhibits NO-induced cell death in IEC-18 cells.

BTZO-2 is an active BTZO-1 derivative, an antioxidant response element-activator, provides protection against lethal endotoxic shock in mice..

BU09059 is a potent, selective, short-acting kappa-opioid receptor antagonist with Ki of 1.72 nM, displays 15- and 616-fold selectivity over μ- and δ-receptors respectively.

Budesonide

Bufalin inhibits steroid receptor coactivator 1 (SRC-1) and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein, and inhibits cancer cell growth both in vitro and in vivo.

Buflomedil HCl

Bumetanide

Buparvaquone(Butalex) is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone; it is a promising compound for the therapy and prophylaxis of all forms of theileriosis.

Bupivacaine HCL

Burimamide oxalate is a potent dual H3/H2 receptor antagonist with Ki of 0.07 and 7.8 uM, respectively.

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well water soluble anti-angiogenic drug that is of potential value in treating choroid neovascularization. Burixafor hydrobromide (TG-0054 hydrobr

Busulfan is a bifunctional alkylating agent.

Butabindide is a potent inhibitor of cholecystokinin-inactivating peptidase/tripeptidyl peptidase 2 (CCK-inactivating peptidase/TPP-2; Ki = 7 nM).1 It is selective for CCK-inactivating peptidase/TPP-2 over a panel of serine proteases (Kis = >1 μM) as well as CCK receptors (Kis = >0.1 mM).

Butenafine

Butyryltimolol is a lipophilic ester prodrug of timolol, a beta adrenergic blocer with antihypertensive and hemodynamic properties.

BV6 induced apoptotic and necrotic cell death in monocytes while T-cells, dendritic cells and macrophages were largely protected against BV6-induced cell death.

BVT 2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor,protecting osteoblasts against endogenous glucocorticoid induced dysfunction.

BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects

BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th

BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM.

BX-320 is a potent, selective and ATP-competitive inhibitor of PDK1 with IC50 of 30 nM, >20-fold selectivity over PKA.

BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

BX-513 hydrochloride inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM).

BX517 is a novel phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

BX-667 is a potent P2Y12 receptor antagonist that blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50=97, 317 and 3000 nM respectively).

BX795 is a potent and selective dual inhibitor of TBK1/PDK1 with IC50s of 2 nM/6 nM respectively; > 50 fold selectivity over PKA, PKC, c-Kit, GSK3β etc.

BX-912 is a selective inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1) with IC50 of 12 nM; >10 fold selectivity over PKA, PKC, C-Kit, EGFR etc.

BXI-72 (NSC334072) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).

BYK191023 (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).

BYK191023 dihydrochloride (BYK-191023) is a potent, highly selective inhibitor of inducible nitric-oxide synthase (iNOS) with IC50 of 86 nM, >20-fold selectivity over nNOS and eNOS (IC50=17 and 162 uM).

BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.

BZ-194 is a small molecule inhibitor of NAADP action that inhibit NAADP-mediated Ca2+ signaling in T cells, neither interferes with Ca2+ mobilization by IP3 or cyclic ADP-ribose nor with capacitative Ca2+ entry.

BzDANP is a small molecule modulator of pre-miR-29a maturation by Dicer, effectively stabilizes the C-bulged RNA and suppresses Dicer-mediated processing of pre-miR-29a in a concentration dependent manner..

Bz-IEGR-pNA is a colorimetric substrate for Factor Xa.

Bz-Nle-Lys-Arg-Arg-AMC is a substrate for dengue virus NS2B-NS3 and yellow fever virus NS3 protease.

C-021 dihydrochloride is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C-021 is a potent and orally bioavailable CCR4 antagonist with IC50 of 0.14 uM and 0.039 uM for inhibition of chemotaxis in human and mouse, respectively..

C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3) with MIC90 of 16 uM against M. tuberculosis..

C25-140 is a specific, first-in-class small molecule inhibitor of the TRAF6-Ubc13 interaction, binds TRAF6, inhibits TRAF6-Ubc13 interaction and TRAF6 activity.

C29 is a potential TLR2 inhibitor.

C2BA-4(C2BA 4) is a potent, specific human Pregnane X receptor (hPXR) activator with EC50 of 49 nM.

C450-0730 is a potent LuxN antagonist that antagonizes LuxN-AI-1 binding with IC50 of 2.7 uM.

C5-benzyl SAHA is a C5-modified SAHA analog that displays dual selectivity to HDAC6 (IC50=0.27 uM) and HDAC8 (IC50=0.38 uM) over HDAC 1, 2, and 3 (IC50=2.9-5.8 uM).

C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM. Preferentially selective for p300 versus other acetyltransferases.

C75 trans is the trans form of C75; C75 is a potent fatty-acid synthase(FASN) inhibitor with IC50 of 35.4 μM(LNCaP cell Proliferation inhibition).

C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.

CA-074 Me is a selective and cell-permeable inhibitor of cathepsin B.

PD-1-IN-17 has CAS#CAS:1673560-66-1, which is a programmed cell death-1 (PD-1) inhibitor. PD-1-IN-17 was first reported in patent WO2015033301A1, (Compound 4), inhibits 92% splenocyte proliferation at 100 nM. PD-1-IN-17 may be related to CA-170 (AUPM170), which is a potent PD-1 inhibitor and curreently under clinical trials.

Ca2+ channel agonist 1 is a N-type Ca2+ channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM.

CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i

CA-5f is a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.

Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.

Cabergoline, an ergot derivative, is a potent dopamine receptor agonist on D2 receptors.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

CaCC(inh)-A01 is a non-selective inhibitor of calcium-activated chloride channels (CaCCs) that blocks ATP-stimulated chloride conductance in human salivary gland, intestinal, and bronchial epithelium (mean IC50 = 10 µM).

CAD-031 (CAD31) is a novel brain penetrant, J147-derivative that has enhanced neurogenic activity over J147 in human neural precursor cells (NPCs).

Cadazolid (ACT-179811) is a novel fluoroquinolone-oxazolidinone antibiotic and a protein synthesis inhibitor.

CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

Calcifediol is a major circulating metabolite of vitamin D3, acting as a competitive inhibitor with an apparent Ki of 3.9 μM, suppresses PTH secretion and mRNA (ED50=2 nM).

Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.

Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.

Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.

Calcium levofolinate (Calcium Folinate)

Calcium polystyrene sulfonate is an ion-exchange resin used for reducing blood levels of potassium. Calcium polystyrene sulfonate is used to treat hyperkalemia in patients with chronic kidney disease (CKD).

Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.

Calhex-231 is a potent negative allosteric modulator of CaSR that blocks calcium-mediated activation with IC50 of 0.39 uM.

Calicheamicin, also known as Calicheamicin gamma(1,I) or Calichemicin gamma1, is an potent enediyne antitumor antibiotics derived from the bacterium Micromonospora echinospora. Calicheamicin targets DNA and cause strand scission. Calicheamicin binds with DNA in the minor groove, wherein it then undergos a reaction analogous to the Bergman cyclization to generate a diradical species. This diradical, 1,4-didehydrobenzene, then abstracts hydrogen atoms from the deoxyribose (sugar) backbone of DNA, which ultimately leads to strand scission. The specificity of binding of calicheamicin to the minor groove of DNA is due to the aryltetrasaccharide group of the molecule.

Calindol hydrochloride is a calcimimetic acting agent and positive allosteric modulator (agonist) of CaSR with EC50 of 0.31 uM (stimulated 3H IP accumulation in CHO cells at 2 mM Ca2+).

Calmidazolium chloride (R 24571) is a calmodulin (CaMK) antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC50s of 0.15 and 0.35 μM, respectively. Also in anti-cancer re

Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 μM) and myosin light chain kinase (IC50 = 51 μM).

calpeptin is Ca2+-dependent protease,calpain inhibitor

CAM4066 (CAM-4066) is a potent and selective CK2α inhibitor with Kd of 0.32 uM and IC50 of 0.37 uM, shows significantly improved selectivity compared to other CK2α inhibitors. .

CAM4712 (CAM-4712) is a potent and selective CK2α inhibitor with IC50 of 7 uM, exhibits cell growth inhibition in HCT116 cell line with IC50 of 10 uM.

Cambendazol is an antihelmintic that, at a dose of 50 mg/kg/day in mice, eradicates S. ratti adult worms from intestine and S. stercoralis larva from muscle.

Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 and 59 μM, respectively.

CAMKK2 inhibitor 4t is a potent, selective, orally available, brain-penetrant CAMKK2 inhibitor with pIC50 of 8.5.

Campesterol is a plant sterol with cholesterol lowering and anticarcinogenic effects.

Camptothecin (CPT) is a potent DNA enzyme topoisomerase I (topo I) inhibitor with an IC50 and IC70 of 50 nM and 0.225 μM for breast cancer cell line MDA-MB-231.